State pharmaceutical assistance for the elderly and disabled: planning issues for program and nonprogram states.

Area of Science:

• Health Policy
• Pharmaceutical Economics
• Public Health

Background:

• High prescription drug costs led to federal and state assistance programs.
• Medicare beneficiaries faced significant out-of-pocket expenses for medications.
• State Pharmaceutical Assistance Programs (SPAPs) served specific populations ineligible for other aid.

Purpose of the Study:

• To assess the impact of the Medicare Catastrophic Coverage Act (MCCA) on state pharmaceutical assistance programs (SPAPs).
• To understand the policy implications of the MCCA's enactment and repeal for prescription drug coverage.
• To gather data on prescription drug programs across all U.S. states and territories.

Main Methods:

• A survey of all U.S. states and territories was conducted.
• Data collection focused on the presence and effects of prescription drug programs.
• The study analyzed the influence of the MCCA on SPAP planning and policy.

Main Results:

• The MCCA's enactment and repeal significantly influenced the planning and policy of SPAPs.
• States without federal programs faced increased pressure to establish their own initiatives.
• The study provided data on the landscape of prescription drug assistance before the MCCA's repeal.

Conclusions:

• The repeal of the MCCA necessitates careful consideration by non-program states initiating their own prescription drug assistance.
• Increasing out-of-pocket and insurance costs continue to drive the need for pharmaceutical support.
• Federal legislative changes have direct and substantial impacts on state-level health programs.